Roche’s Accu-Chek SmartGuide CGM System Gains CE Mark for Diabetic Patients


Roche’s Accu-Chek SmartGuide CGM system has obtained CE Mark for type 1 & type 2 diabetic patients (18yrs.) on flexible insulin therapy. It will be introduced in the upcoming months
The system’s efficacy was established in a trial showing a mean absolute relative difference (MARD) of 9.2% & 99.8% in glucose values within zones A & B on the Parkes Error Grid with its predictive features exceeding in accuracy, sensitivity, specificity & event detection
The system comprises an Accu-Chek SmartGuide CGM sensor, SmartGuide App & SmartGuide Predict App. The sensor sends real-time glucose values to the SmartGuide app and the Predict app identifies patterns, predicts future glucose levels & indicates hypoglycemia risk within 30mins.

Ref: Roche | Image: Roche

Related News:- Roche’s Vabysmo Prefilled Syringe Receives the US FDA’s Approval for Vision Loss

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at